The effect of erythromycin on the pharmacokinetics and pharmacodynamics of zopiclone
- PMID:7833227
- PMCID: PMC1364781
- DOI: 10.1111/j.1365-2125.1994.tb04367.x
The effect of erythromycin on the pharmacokinetics and pharmacodynamics of zopiclone
Abstract
1. The effect of erythromycin on the pharmacokinetics and pharmacodynamics of oral zopiclone, a non-benzodiazepine hypnotic, was investigated in a double-blind, cross-over study. 2. Ten healthy volunteers were given placebo or 500 mg erythromycin orally three times a day for 6 days followed by an oral dose of 7.5 mg zopiclone. 3. Erythromycin increased plasma zopiclone concentration by 4-fold at 0.5 h (P < 0.05) and by 2-fold at 1 h (P < 0.05). There were increases of 3- and 2-fold in the AUC(0,1 h) and AUC(0,2 h) values (P < 0.05). The total AUC of zopiclone increased by 80% (P < 0.05) but the peak concentration by only 40% (P < 0.05). The peak time of zopiclone concentration was reduced from 2 to 1 h (P < 0.001). 4. Significant pharmacodynamic differences between the treatments were observed from 0.5 h to 2 h with respect to saccadic latency and digit symbol substitution tests. 5. The interaction between erythromycin and zopiclone resulted mainly in accelerated absorption which may lead to a faster hypnotic effect in patients.
Similar articles
- Clinical pharmacokinetics of zopiclone.Fernandez C, Martin C, Gimenez F, Farinotti R.Fernandez C, et al.Clin Pharmacokinet. 1995 Dec;29(6):431-41. doi: 10.2165/00003088-199529060-00004.Clin Pharmacokinet. 1995.PMID:8787948Review.
- Concentrations and effects of zopiclone are greatly reduced by rifampicin.Villikka K, Kivistö KT, Lamberg TS, Kantola T, Neuvonen PJ.Villikka K, et al.Br J Clin Pharmacol. 1997 May;43(5):471-4. doi: 10.1046/j.1365-2125.1997.00579.x.Br J Clin Pharmacol. 1997.PMID:9159561Free PMC article.Clinical Trial.
- Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zopiclone.Jalava KM, Olkkola KT, Neuvonen PJ.Jalava KM, et al.Eur J Clin Pharmacol. 1996;51(3-4):331-4. doi: 10.1007/s002280050207.Eur J Clin Pharmacol. 1996.PMID:9010708Clinical Trial.
- Actions of zopiclone and carbamazepine, alone and in combination, on human skilled performance in laboratory and clinical tests.Kuitunen T, Mattila MJ, Seppälä T, Aranko K, Mattila ME.Kuitunen T, et al.Br J Clin Pharmacol. 1990 Sep;30(3):453-61. doi: 10.1111/j.1365-2125.1990.tb03797.x.Br J Clin Pharmacol. 1990.PMID:2223424Free PMC article.Clinical Trial.
- Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone.Drover DR.Drover DR.Clin Pharmacokinet. 2004;43(4):227-38. doi: 10.2165/00003088-200443040-00002.Clin Pharmacokinet. 2004.PMID:15005637Review.
Cited by
- Zopiclone. An update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia.Noble S, Langtry HD, Lamb HM.Noble S, et al.Drugs. 1998 Feb;55(2):277-302. doi: 10.2165/00003495-199855020-00015.Drugs. 1998.PMID:9506247Review.
- The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone.Tornio A, Neuvonen PJ, Backman JT.Tornio A, et al.Eur J Clin Pharmacol. 2006 Aug;62(8):645-51. doi: 10.1007/s00228-006-0155-6. Epub 2006 Jul 11.Eur J Clin Pharmacol. 2006.PMID:16832679Clinical Trial.
- Metabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zoplicone, and zolpidem.Chouinard G, Lefko-Singh K, Teboul E.Chouinard G, et al.Cell Mol Neurobiol. 1999 Aug;19(4):533-52. doi: 10.1023/a:1006943009192.Cell Mol Neurobiol. 1999.PMID:10379424Free PMC article.Review.
- Improving antibacterial prescribing safety in the management of COPD exacerbations: systematic review of observational and clinical studies on potential drug interactions associated with frequently prescribed antibacterials among COPD patients.Wang Y, Bahar MA, Jansen AME, Kocks JWH, Alffenaar JC, Hak E, Wilffert B, Borgsteede SD.Wang Y, et al.J Antimicrob Chemother. 2019 Oct 1;74(10):2848-2864. doi: 10.1093/jac/dkz221.J Antimicrob Chemother. 2019.PMID:31127283Free PMC article.
- Clinical pharmacokinetics of zopiclone.Fernandez C, Martin C, Gimenez F, Farinotti R.Fernandez C, et al.Clin Pharmacokinet. 1995 Dec;29(6):431-41. doi: 10.2165/00003088-199529060-00004.Clin Pharmacokinet. 1995.PMID:8787948Review.
References
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources